ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Seroprevalence against measles, Austria, stratified by birth years 1922 to 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Waning Measles Immunity and Sustained Rubella Seroprotection Among Adults in Istanbul, Türkiye.Medicina (Kaunas, Lithuania) · 2026Article
- Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population.Infection · 2026Article
- Measles Seroprevalence Among Healthcare Workers in a Tertiary Hospital in Central Greece, 2017.Vaccines · 2026Article
- Duration of vaccine-induced immunity following MMR2 vaccination in a measles and rubella-eliminated country.International journal of epidemiology · 2026Article
- Measles - retrospective study of cases reported in a national notification system, Czech Republic, 2018-2024.BMC public health · 2026Article
- Article
- Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape.Vaccines · 2026Article
- Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- The Unprotected: Measles Seroprevalence in Children During the First Two Years of Life.Viruses · 2025Article
- Seroprevalence of Measles-, Mumps-, and Rubella-Specific Antibodies in Future Healthcare Workers in Serbia: A Cross-Sectional Study.Vaccines · 2025Article
- Surge in Measles Cases in Italy from August 2023 to January 2025: Characteristics of Cases and Public Health Relevance.Vaccines · 2025Article
- Review
- Sustaining successes and addressing challenges to vaccination - a continued public health mission.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundVaccination programmes initiated in the early 1970s reduced the incidence of measles in Austria, which resulted in the interruption of endemic measles virus (MeV) circulation and the achievement of elimination status in 2018. However, large outbreaks occurred in 2023 and 2024.AimBy assessing MeV-specific IgG antibody levels, we analysed if immunity recently declined due to the COVID-19 pandemic, vaccine-induced immunity waned over long term or immunity gaps already pre-existed in the population.MethodsWe determined anti-MeV antibody levels in a retrospective dataset of 56,360 diagnostic samples (from 50,754 individuals) collected 2010-2024 and correlated antibody cutoffs to titres from a live-virus neutralisation test.ResultsIndividuals born before 1970 (n = 15,007) had antibody levels > 3,000 IU/L, persisting into higher age, and < 2% (n = 300) of them were seronegative. In contrast, individuals born after 1990 (n = 12,778) displayed seronegativity rates of 13-20% and lower median antibody concentrations in seropositive individuals (449-773 IU/L). In these individuals, antibody levels decreased noticeably between the ages of 2 and 10 years but remained stable between those aged 10 and 30 years. There was no significant difference in seronegativity rates at the age of 12-24 months in children born 2016-2019 and 2020-2022 (the years of the COVID-19 pandemic).ConclusionIn Austria, there are significant immunity gaps in individuals born after 1970, which pre-existed before the COVID-19 pandemic. Thus, young and middle-aged populations not immune against measles should be vaccinated to counteract a further decline of immunity at the population level and prevent outbreaks whenever MeV is imported.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.